Cargando…
State of the Art: Lipoproteinapherese
Lipoprotein apheresis (LA) is usually a last resort in cardiovascular high-risk patients in the context of secondary prevention after lifestyle measures and maximal pharmacotherapy have failed to prevent the occurrence of new atherosclerotic cardiovascular events (ASCVDE) or to achieve the internati...
Autores principales: | Schatz, Ulrike, Schettler, Volker J.J., Julius, Ulrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060055/ https://www.ncbi.nlm.nih.gov/pubmed/36990113 http://dx.doi.org/10.1055/a-1516-2761 |
Ejemplares similares
-
Erratum: State of the Art: Lipoproteinapherese
por: Schatz, Ulrike, et al.
Publicado: (2023) -
State of the Art: Therapie mit Statinen
por: Laufs, Ulrich, et al.
Publicado: (2021) -
Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?
por: Julius, Ulrich, et al.
Publicado: (2020) -
Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels
por: Schettler, Volker J. J., et al.
Publicado: (2015) -
Successful completion of pregnancy using apheresis and a balanced dose of coagulation factors in the presence of high thrombophilia and Lp(a) levels in a woman with two previous abortions
por: Schettler, Volker J.J., et al.
Publicado: (2014)